Computationally Designed VLP Vaccines
By utilizing computationally designed proteins that self-assemble into virus-like particles (VLPs), we are able to readily manufacture VLPs displaying complex antigens to target significant unmet medical needs.
RSV, hMPV, and SARS-CoV-2 Vaccines
Our vaccine candidates for respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, have the potential to induce high neutralizing antibody titers for more effective protection.
Icosavax is dedicated to advancing vaccines against severe life-threatening respiratory diseases to protect our most at-risk populations.
In the News
Mr. Russo brings more than 25 years of diverse industry experience, including in finance and operations for public biotechnology companies, as a sell-side equity research analyst covering biotechnology, and in operations and vaccine manufacturing for a large pharma company.
First participants dosed in a Phase 1 clinical trial to assess safety and efficacy of IVX-411 with or without Seqirus Inc.’s proprietary adjuvant MF59® in subjects naïve to COVID-19
Icosavax Closes $100 Million Series B Financing to Advance Bivalent RSV/hMPV Vaccine Candidate Into Clinical Trials
Company’s novel computationally designed virus-like particle (VLP) technology has the potential to create safe, effective, and durable vaccines against life-threatening respiratory viruses in older adults